Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Comments to the article “Streptococcus pyogenes infections in Spanish children...
Journal Information
Vol. 42. Issue 2.
Pages 114-115 (February 2024)
Share
Share
Download PDF
More article options
Vol. 42. Issue 2.
Pages 114-115 (February 2024)
Letter to the Editor
Full text access
Comments to the article “Streptococcus pyogenes infections in Spanish children before and after the COVID pandemic. Coming back to the previous incidence”
Comentarios sobre el artículo “Infecciones por Streptococcus pyogenes en niños españoles antes y después de la pandemia. Volviendo a la incidencia previa”
Visits
183
María de Ceano-Vivasa,1,
Corresponding author
maria.dceano@salud.madrid.org

Corresponding author.
, Miguel Ángel Molina Gutiérreza,1, Rosario López Lópeza, Cristina Calvob,c,d,e
a Pediatric Emergency Department, La Paz University Hospital, Madrid, Spain
b Pediatric Infectious Diseases Department, La Paz University Hospital, Spain
c Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
d Translational Research Network in Pediatric Infectious Diseases (RITIP), Madrid, Spain
e CIBER de Enfermedades Infecciosas, CIBERINFEC, ISCIII, Madrid, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
Dear Editor,

As a follow-up to the article published in your journal entitled “Streptococcus pyogenes infections in Spanish children before and after the COVID pandemic. Coming back to the previous incidence”,1 we would like to add some comments regarding Group A Streptococcus (GAS) infections incidence during the first semester of 2023.

In our series, mild GAS infections (tonsillopharyngitis and scarlet fever) and invasive GAS infections (iGAS) decreased significantly during the pandemic period. Throughout 2022 we observed a reemergence of GAS infections reaching the pre-pandemic levels, but not higher1 than described in the United Kingdom alert published in December 20222 and confirmed in other countries.3 Considering that we may have identified the beginning of the outbreak, we completed the study during the first half of 2023.

Between January and June 2023, our emergency department (ED) attended 625 patients with confirmed GAS infection, 609 mild infections and 16 iGAS infections. The median age of the patients was 6.3 years (RIC: 4.2–8.5); 33.3% were aged 0–4 years, being this age distribution similar to that found in 2019. Fifty-six percent were male (350/625).

The incidence of GAS infections during the first semester 2023 was 22.9/1000 ED visits, reaching double that observed in 2022 (10.2/1000 ED visits) and 2019 (12.4/1000 ED visits) respectively. The incidence of iGAS infections also increased during these first months of 2023 (0.6/1000 ED visits), reaching nearly three times the incidence observed in 2022 (0.2/1000 ED visits) and one and a half times that of 2019 (0.4/1000 ED visits) (Fig. 1). These findings are like those published in Europe during the last months of 2022.4–6

Fig. 1.

(A) Incidence of invasive GAS infections during the study period. (B) Incidence of non-invasive GAS infections during the study period. GAS: Group A Streptococcus; ED: emergency department.

(0.32MB).

The most frequent invasive disease during the first 6 months of 2023 was mastoiditis (7/16 iGAS; 43.8%) of which 4 had local complications, while in 2022 mastoiditis accounted for 18.2% (2/11) of the iGAS. The remaining invasive diseases were 3 pneumonias, 2 meningitis, one sepsis, one epidural abscess, one orbital cellulitis complicated with subperiosteal abscess, and one peritonsillar abscess.

Although we have not serotyped our GAS strains, the study cited here describes a continuous increase in emm type 1 cases throughout 2022, with a peak occurring during the latter part of the year, being the months with the highest number of cases.5 Furthermore, another study focusing on adults with severe pulmonary GAS infections in Scotland observed a significant predominance of the M1UK strain during the ongoing outbreak.7

In our series there were no varicella cases prior to iGAS infections as described by other authors,5,6 but 5 of the 16 patients with invasive infection were associated with co-infection with other respiratory viruses: two influenza, two SARS-CoV-2 and one respiratory syncytial virus. Viral infections may have amplified the resurgence of iGAS infections during these months.5 In our series, we did not have any deaths.

In summary, in our series including the first semester of 2023 as in other countries, GAS infections decreased markedly during the COVID-19 pandemic, but in the post-pandemic period there has been a considerable increase in both mild and severe cases, reaching figures similar to those detected in other European countries. This delay in the increase of streptococcal infections in our region has had a parallel course to influenza infections in Spain during winter 2022–2023.

Maintain a close surveillance of S. pyogenes infections in the coming months and years will be relevant to know the trend and risk factors of these infections, especially invasive ones.

Financial disclosure

The authors have no financial relationships relevant to this article to disclose.

Conflict of interest

The authors declare no conflict of interest.

References
[1]
M. De Ceano-Vivas, M.Á. Molina Gutiérrez, I. Mellado-Sola, P. García Sánchez, D. Grandioso, C. Calvo.
Streptococcus pyogenes infections in Spanish children before and after the COVID pandemic. Coming back to the previous incidence.
Enferm Infecc Microbiol Clin (Engl Ed), (2023),
[2]
UK Health Security Agency. UKHSA update on scarlet fever and invasive group A strep. Latest data from the UK Health Security Agency (UKHSA) on scarlet fever and invasive group A strep cases. 2 December 2022. Available from: https://www.gov.uk/government/news/ukhsa-update-on-scarlet-fever-and- invasive-group-a-strep-1 [accessed 28.12.22].
[3]
S.N. Ladhani, R. Guy, S.S. Bhopal, C.S. Brown, T. Lamagni, A. Sharp.
Paediatric group A streptococcal disease in England from October to December, 2022.
Lancet Child Adolesc Health, 7 (2023), pp. e2-e4
[4]
World Health Organization. Increased incidence of scarlet fever and invasive group A Streptococcus infection – multi-country [WHO web site]. 15 December 2022. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON429 [accessed 28.12.22].
[5]
B. de Gier, N. Marchal, I. de Beer-Schuurman, M. Te Wierik, M. Hooiveld, ISIS-AR Study Group, et al.
Increase in invasive group A streptococcal (Streptococcus pyogenes) infections (iGAS) in young children in the Netherlands, 2022.
[6]
R. Guy, K.L. Henderson, J. Coelho, H. Hughes, E.L. Mason, S.M. Gerver, et al.
Increase in invasive group A streptococcal infection notifications, England, 2022.
[7]
P.J.B. Davies, C.D. Russell, A.R. Morgan, S.K. Taori, D. Lindsay, R. Ure, et al.
Increase of severe pulmonary infections in adults caused by M1UKStreptococcus pyogenes, Central Scotland, UK.
Emerg Infect Dis, 29 (2023), pp. 1638-1642

These authors contributed equally.

Copyright © 2023. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos